Fabio Volterra, MD
Hematology & Oncology · Bronx, NYNPI 1841289931
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.0%), education and consulting fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Novartis at 24.2% of the total. Reporting peaked in 2023 at $472 and has fallen 75.3% since, to $116 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 29 payments — averaging $37.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$263
- Johnson & Johnson$147
- AbbVie$125
- Gilead$85
- Exelixis Inc.$85
- AstraZeneca$83
- plus $298 from 13 others
Across 58 payments — averaging $29,919 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.6M
- Bristol Myers Squibb$55K
- Spectrum Pharmaceuticals Inc.$27K
- Amgen$11K
- E.r. Squibb & Sons, L.L.C.$9K
- Pharmacyclics LLC, An Abbvie Company$5K
- plus $2K from 2 others
What the payments were for
- Consulting fees$26324%
- Food & beverage$54350%
- Education$28026%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $263 |
| Johnson & Johnson | 5 | $147 |
| AbbVie | 1 | $125 |
| Gilead(2 entities) | 4 | $85 |
| Exelixis Inc. | 1 | $85 |
| AstraZeneca | 2 | $83 |
| GE HealthCare | 1 | $71 |
| Lexicon Pharmaceuticals, Inc. | 2 | $38 |
| Epizyme, Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Advanced Accelerator Applications | 1 | $16 |
| Array Biopharma Inc | 1 | $14 |
| Pfizer | 1 | $14 |
| Merck | 1 | $13 |
| Seagen Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,086 in reported general payments places this provider in the 45th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 116 | $2,012,497 |
| VerzenioAbemaciclib | 61 | $940,578 |
| ImbruvicaIbrutinib | 39 | $596,805 |
| AranespDarbepoetin Alfa In Polysorbat | 162 | $506,692 |
| IdhifaEnasidenib Mesylate | 12 | $411,196 |
| XgevaDenosumab | 111 | $336,474 |
| XtandiEnzalutamide | 22 | $303,686 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 18 | $301,061 |
| BrukinsaZanubrutinib | 19 | $294,680 |
| ProcritEpoetin Alfa | 94 | $288,615 |
| SprycelDasatinib | 17 | $287,948 |
| KisqaliRibociclib Succinate | 19 | $284,418 |
| Neulasta OnproPegfilgrastim | 46 | $283,267 |
| LenvimaLenvatinib Mesylate | 11 | $270,539 |
| KyprolisCarfilzomib | 27 | $238,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Tasigna, Sandostatin Lar Depot | $263 | $580,83842 claims |
| Johnson & JohnsonProcrit | $147 | $288,61594 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $17 | $287,94817 claims |
| AstraZenecaCalquence | $83 | $201,74213 claims |
| AbbVieLupron Depot | $125 | $196,17371 claims |
| PfizerIbrance, Eliquis | $14 | $191,66029 claims |
| MerckKeytruda | $13 | $178,51016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Bronx
- Tauseef AhmedBronx$171K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.